Amyloidosis News and Research

RSS
Amyloidosis is the term applied to a group of conditions caused by deposits of an abnormal protein called amyloid. This rare but serious condition affects between 1 and 5 people in every 100,000 each year in the UK. The condition is mainly seen among the elderly.
Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

Limited positive effect of Tafamidis in neurological disorders

Limited positive effect of Tafamidis in neurological disorders

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

Alnylam announces complete results from ALN-RSV01 Phase IIb trial on RSV infection

New results describe development of DC cancer vaccine with enhanced immunogenic potential

New results describe development of DC cancer vaccine with enhanced immunogenic potential

BUSM part of Transthyretin Amyloidosis Cardiac Study

BUSM part of Transthyretin Amyloidosis Cardiac Study

Hint of tafamidis benefit in rare polyneuropathy

Hint of tafamidis benefit in rare polyneuropathy

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

New paper documents discovery of novel lipids, including MC3

New paper documents discovery of novel lipids, including MC3

BWH performs New England's first implant of SynCardia temporary Total Artificial Heart

BWH performs New England's first implant of SynCardia temporary Total Artificial Heart

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

Pfizer receives FDA Complete Response Letter for tafamidis meglumine NDA

Pfizer receives FDA Complete Response Letter for tafamidis meglumine NDA

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Study shows how tafamidis drug works against amyloid disease

Study shows how tafamidis drug works against amyloid disease

FDA advisory committee votes in favor of Pfizer's tafamidis meglumine

FDA advisory committee votes in favor of Pfizer's tafamidis meglumine

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam first quarter revenues decrease to $20.6 million

Alnylam first quarter revenues decrease to $20.6 million

Nephros granted rights to market products based on Medica's Medisulfone ultrafiltration technology

Nephros granted rights to market products based on Medica's Medisulfone ultrafiltration technology